423: Prognostic significance of serum Neutrophil gelatinase-associated lipocalin (NGAL) levels in pre-eclampsia and eclampsia


      To The study aims to evaluate the levels of circulating sFlt-1 in pre-eclampsia (PE) and eclampsia patients and to assess its prognostic significance in detection of PE complications.

      Study Design

      The current study was a prospective cohort study conducted in tertiary University hospital between January and December 2016. Included patients were divided into two groups; (Group I) severe PE group and (Group II) eclampsia group. Age, parity and gestational age matched women had approached to participate in the study as a control group (Group III). Serum NGAL levels were measured at inclusion with all basic investigations. Patients were followed up until delivery to record any complications. Correlation analysis was performed between the serum NGAL levels and clinical, laboratory investigations. Receiver operating characteristic analysis was constructed for the evaluation of the area under curve (AUC) as well as the sensitivity and specificity regarding the cutoff point of NGAL level that predict occurrence of complications.


      The study included 94 women. Women with complicated severe PE showed higher NGAL levels than in non complicated cases (1149.1 ±252.9 versus 845.8±270.9, p=0.04 Similarly, the mean serum level of NGAL in complicated eclampsia was higher than in non-complicated cases (2313.3 ±1215.2 versus 1526.9 ±821.9, p<0.001) (OR=1.004, 95% CI: 1.002-1.006, p<0.001). NGAL levels were strongly correlated with SBP (r=0.585) and DBP (r=0.564) (p<0.001 and p<0.001 respectively). At cutoff point 1099.39 ng/ml of NGAL serum levels, the sensitivity was 70% and specificity was 76.7% with AUC=0.881, 95% CI: 0.803-0.959.


      Serum NGAL could be used as a prognostic marker to predict the occurrence of complications of in cases of PE and eclampsia.
      Figure thumbnail fx1